Gadolin Research

Gadolin Research is a clinical research site network based in Beaumont, Texas, specializing in conducting clinical trials across all phases (Phases 1-4). The company focuses on bringing cutting-edge medical research and therapeutic equity to diverse and underserved populations in Southeast Texas. Gadolin Research has managed over 300 clinical trials in partnership with major pharmaceutical companies and contract research organizations (CROs), contributing to the FDA approval of breakthrough treatments such as Kisunla (donanemab) for Alzheimer's disease and Abrysvo for RSV. As a member of the Global Alzheimer's Platform Foundation network (GAP-Net), the site is particularly recognized for its expertise in neurodegenerative and central nervous system (CNS) research, alongside trials in vaccines, women's health, psychiatry, and pediatric weight management.